Cochrane · systematic review · CD012368
Metformin and second‐ or third‐generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus
Madsen, KS, Kähler, P, Kähler, LKA, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
Metabolic and Endocrine DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
12
No studies
3
Included studies
NR
No studies 3 · 18.8%Ungraded 1 · 6.3%Very low 6 · 37.5%Low 6 · 37.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy compared with metformin plus another antidiabetic drug for adults with type 2 diabetes mellitus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality (N) Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | NR | No studies |
M + GLP1‐A Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 1.15 [0.49, 2.67] | 3 studies · 2594 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
M + DPP4‐I Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 1.32 [0.76, 2.28] | 9 studies · 11694 participants | Low Downgraded: imprecision, inconsistency |
M + thiazolidinedione Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 1.09 [0.85, 1.4] | 6 studies · 6654 participants | Low Downgraded: imprecision, inconsistency |
M + nateglinide Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | 3 studies · 874 participants | Low Downgraded: imprecision, inconsistency |
M + SGLT2‐I Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 0.96 [0.44, 2.09] | 4 studies · 5134 participants | Very low Downgraded: imprecision, inconsistency |
M + nateglinide Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | 2 studies · 446 participants | Low |
M + nateglinide Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 1.68 [0.54, 5.21] | 3 studies · 874 participants | Low |
Non‐fatal stroke (N) Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | NR | No studies |
M + GLP1‐A Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | 4 participants | Ungraded |
M + DPP4‐I Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 2.21 [0.74, 6.58] | 4 studies · 5093 participants | Very low |
M + thiazolidinedione Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 1.29 [0.67, 2.47] | 2 studies · 3123 participants | Very low |
M + nateglinide Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | 1 study · 233 participants | Very low |
M + SGLT2‐I Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | RR 0.87 [0.22, 3.34] | 2 studies · 2775 participants | Very low |
M + DPP4‐I Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | 1 study · 64 participants | Very low |
Health‐related quality of life Metformin‐sulphonylurea (second‐ or third‐generation) combination therapy vs metformin plus another antidiabetic drug | no estimate extracted | NR | No studies |